IMRT同步推量在乳腺癌辅助放疗中缩短疗程且非劣于常规序贯推量
这项前瞻性多中心随机III期试验(IMRT-MC2)纳入502例保乳术后乳腺癌患者,比较常规分割IMRT同步推量(IMRT-SIB)与3D-CRT序贯推量的非劣效性。IMRT-SIB显著缩短辅助放疗时间而不影响临床结局。
要点
- IMRT-SIB的2年局部控制率非劣于3D-CRT序贯推量(99.6% vs 99.6%)。
- 放疗后6周和2年美容效果(pBRA)两组非劣效,不良事件无显著差异。
- IMRT-SIB可显著缩短辅助放疗总疗程,且不影响临床结局。
核心结论
- IMRT-SIB在2年局部控制和美容效果方面非劣效于3D-CRT序贯推量,且显著缩短辅助放疗时间而不影响临床结局。
研究设计与样本
- 前瞻性、多中心、随机III期试验(NCT01322854),2011至2015年共随机分配502例乳腺癌患者。
- 比较常规分割IMRT同步推量(IMRT-SIB)与3D适形放疗序贯推量(3-D-CRT-seqB)。
- 主要终点为2年和5年局部控制率(非劣效界值HR 3.5)以及放疗后6周和2年美容效果(pBRA评分,非劣效界值1.25)。
主要发现
- 患者和治疗医师按Harvard量表评估的美容效果及LENT-SOMA晚期毒性评估两组无显著差异。
关键数值与推荐
- 局部控制非劣效界值为HR 3.5。
- 美容效果(pBRA)非劣效界值为1.25。
临床怎么用
- 对于保乳术后需辅助放疗的乳腺癌患者,可采用IMRT-SIB替代3D-CRT序贯推量以缩短治疗时间。
- 该方案在2年局部控制和美容效果上不劣于传统序贯推量方案。
局限性
- 原文未报告5年局部控制率结果。
- 随访时间有限,中位随访5.1年,长期结局需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the modern era, improvements in radiation therapy techniques have paved the way for simultaneous integrated boost irradiation in adjuvant breast radiation therapy after breast conservation surgery. Nevertheless, randomized trials supporting the noninferiority of this treatment to historical standards of care approach are lacking. METHODS: A prospective, multicenter, randomized phase 3 trial (NCT01322854) was performed to analyze noninferiority of conventional fractionated intensity modulated radiation therapy with simultaneous integrated boost (IMRT-SIB) to 3-D conformal radiation therapy with sequential boost (3-D-CRT-seqB) for breast cancer patients. Primary outcomes were local control (LC) rates at 2 and 5 years (noninferiority margin at hazard ratio [HR] of 3.5) as well as cosmetic results 6 weeks and 2 years after radiation therapy (evaluated via photo documentation calculating the relative breast retraction assessment [pBRA] score [noninferiority margin of 1.25]). RESULTS: A total of 502 patients were randomly assigned from 2011 to 2015. After a median follow-up of 5.1 years, the 2-year LC for the IMRT-SIB arm was noninferior to the 3-D-CRT-seqB arm (99.6% vs 99.6%, respectively; HR, 0.602; 95% CI, 0.123-2.452; P = .487). In addition, noninferiority was also shown for cosmesis after IMRT-SIB and 3-D-CRT-seqB at both 6 weeks (median pBRA, 9.1% vs 9.1%) and 2 years (median pBRA, 10.4% vs 9.8%) after radiation therapy (95% CI, -0.317 to 0.107 %; P = .332). Cosmetic assessment according to the Harvard scale by both the patient and the treating physician as well as late-toxicity evaluation with the late effects normal tissues- subjective, objective, management, analytic criteria, a score for the evaluation of long-term adverse effects in normal tissue, revealed no significant differences between treatment arms. In addition, there was no difference in overall survival rates (99.6% vs 99.6%; HR, 3.281; 95% CI: -0.748 to 22.585; P = .148) for IMRT-SIB and 3-D-CRT-seqB, respectively. CONCLUSIONS: To our knowledge, this is the first prospective trial reporting the noninferiority of IMRT-SIB versus 3-D-CRT-seqB with respect to cosmesis and LC at 2 years of follow-up. This treatment regimen considerably shortens adjuvant radiation therapy times without compromising clinical outcomes.
引用
- Hörner-Rieber J, Forster T, Hommertgen A, et al. Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). Int J Radiat Oncol Biol Phys. 2020. PMID: 33321192. doi:10.1016/j.ijrobp.2020.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。